ACADIA Pharmaceuticals (ACAD) vs Dyne Therapeutics (DYN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dyne Therapeutics (DYN) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 14.5% versus a loss of 8.8%. Over five years, ACAD leads with a +12.2% price change compared with +7.3% for DYN. ACADIA Pharmaceuticals is the larger company by market cap ($3.37 billion vs $3.06 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | DYN |
|---|---|---|
| Share price | $19.58 | $16.37 |
| Market cap | $3.37B | $3.06B |
| 1-day change | -0.36% | +2.50% |
| YTD return | -26.43% | -18.35% |
| 1-year return | -8.77% | +14.48% |
| 5-year return | +12.22% | +7.33% |
| P/E ratio (TTM) | 8.78 | — |
| Forward P/E | 22.04 | — |
| EPS (TTM) | $2.23 | $-3.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.07B | — |
| Revenue growth (YoY) | +11.87% | — |
| Net income (latest FY) | $391.00M | $-446.21M |
| Gross margin | 91.69% | — |
| Operating margin | 9.78% | — |
| Net margin | 36.49% | — |
| 52-week high | $30.96 | $27.31 |
| 52-week low | $19.32 | $13.73 |
| Distance from 52-week high | -36.76% | -40.05% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +64.25% | +119.91% |
| Average volume | 1.84M | 2.78M |
| Shares outstanding | 172.31M | 186.75M |
| Employees | 796 | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYN has outperformed ACAD by 23.3 percentage points over the past year.
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 289 employees
ACAD vs DYN FAQ
Which is bigger, ACADIA Pharmaceuticals or Dyne Therapeutics?
ACADIA Pharmaceuticals (ACAD) is larger, with a market capitalization of $3.37B compared with $3.06B for Dyne Therapeutics (DYN).
Which stock has performed better over the past year, ACAD or DYN?
DYN returned +14.48% over the past 12 months, compared with -8.77% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Are ACADIA Pharmaceuticals and Dyne Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.